Introduction Although aspirin (ASA) is the mainstay of treatment for the prevention of
recurrent ischemic stroke, the Clopidogrel versus Aspirin in Patients at Risk of Ischemic …

Background Other than aspirin, there are few oral antithrombotic treatments with proven
efficacy in patients with acute coronary syndrome. In this report, we present the rationale …

Background—We studied the benefits and risks of adding clopidogrel to different doses of
aspirin in the treatment of patients with acute coronary syndrome (ACS). Methods and …

Background: Clopidogrel use as single antiplatelet therapy (SAPT) has never been
evaluated in stable coronary artery disease (CAD) outpatients either as compared to …

Background There is no clear consensus on whether aspirin offers better outcomes in terms
of secondary cardiovascular disease prevention compared with clopidogrel. Objective The …

Platelets play a pivotal role in the pathogenesis of atherothrombosis, believed to be
integrally involved in both the development and progression of atherosclerotic heart …

The possible additive antiplatelet effects of aspirin and clopidogrel have been explored in
the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management …

Background and Purpose—The goal of this study was to examine the influence of
preexisting symptomatic atherosclerotic disease on subsequent ischemic event rates and …

Background—The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial
demonstrated that clopidogrel, given early and continued long term, was superior to placebo …

All patients with stable coronary artery disease require medical therapy to prevent disease
progression and recurrent cardiovascular events. Three classes of medication are essential …